Recursion Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Recursion Pharmaceuticals

24/02/2024 02:03

* Recursion Pharmaceuticals Inc  RXRX.OQ   RXRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 27 for the period ending December 31 2023
    * The Salt Lake City Utah-based  company is expected to
report a
48.8% increase in revenue to $20.353 million from $13.68 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Recursion
Pharmaceuticals Inc
is for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Recursion
Pharmaceuticals Inc is $12.50​, below​ its last closing price
of $13.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.38      -0.43     Missed  -11.7
 Jun. 30 2023  -0.38       -0.37      -0.38     Missed  -1.5
 Mar. 31 2023  -0.34       -0.35      -0.34     Beat    2.3​
 Dec. 31 2022  -0.31       -0.29      -0.31     Missed  -6.9
 ​​Sep.        -0.38       -0.38      -0.35     Beat    7.3
 30 2022                                                
 Jun. 30 2022  -0.38       -0.37      -0.38     Missed  -1.8​
 Mar. 31 2022  0.12        0.10       -0.33     Missed  -430
 Dec. 31 2021              -0.31      -0.38     Missed  -23.9
 This summary was machine generated February 24 at 02:03 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)